Wout Devlies

Prostate Cancer Aficionado. Research @KU_Leuven @DanaFarber and @UCLcancer, EAU guideline associate @uroweb, Urology Resident @UZLeuven

[Wout Devlies @WoutDevlies]

Out now: joint analysis of single cell and spatial transcriptomic data from 120 patients. Proud of this team effort!

[Antti Kiviaho @KiviahoAntti]

Our investigation into the prostate tumor microenvironment is now out in Nature Comms: https://t.co/RGH9XdKo9B

We combined publicly available scRNA-seq data with in-house spatial transcriptomics samples to jointly anayze data from 120 patients. Here’s what we found �� 1/6

[Bram De Laere @BramDL]

Privileged seeing the @ProBioTrial published in @NatureMedicine

My sincerest gratitude for all the dedicated doctors, nurses, lab personnel, trial managers, and most importantly, the patients who made this possible🙏

Thank you @komop_tgkanker for making ProBio possible in🇧🇪

[European Urology @EUplatinum]

European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines by Jennifer Kranz et al.

Full article: https://t.co/ucY60VHH2p

@riccabar1 @rajan_vpillay @BauschKathrin @WoutDevlies @LeitnerLorenz @ManticaGu @GBonkat

#Medtwitter #UroSoMe

[Juan Cristóbal Bravo @BravoiJc]

Amazing experience STEPS program! Nice Uroonco24. Thanks to the experts and colleagues!

[Wout Devlies @WoutDevlies]

Proud of our work from the Boston Lab on RT after neoadjuvant treatments in high-risk localized PCa: adjuvant RT rarely used and outcomes of both adjuvant and salvage poor. Patient selection will be key!

[Praful Ravi @PrafulRavi1]

Outcomes of adjuvant and salvage RT in patients who have received neoadjuvant ARPI prior to RT for high-risk prostate cancer: our pooled analysis of trial patients published in #Prostatejournal - https://t.co/6IGw0RCCey

[Alexander Giesen @TheGiesen]

"Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients"
@joniau @LoicBaekelandt @WoutDevlies @devos_gaetan @EveraertsW
https://t.co/vCc90qgqzf

[Karel David @KarelDavid_]

Happy to see our work highlighted during this #Movember month! Don't forget the impact of #androgendeprivation on #bone in #prostatecancer patients! https://t.co/lKB90ONuv1
Great collaboration with our urology department @devos_gaetan @WoutDevlies @joniau
👇👇👇

[Alexander Giesen @TheGiesen]

🔬 #PROpel unveiled PARP-inhibitors potential in #PCa, unveiling new potential synergies beyond HRRm!
🎯 More trials are needed for validation beyond pre-clinical data and pinpointing the ARSI + PARPi synergy in non-HRRm patients!
@joniau @WoutDevlies
https://t.co/8tm40k2Ee7

[Wout Devlies @WoutDevlies]

Discover our work on the value of cystoscopy in bladder cancer detection, laying the basis for European and Canadian guidelines. Big team effort!

[Imran Omar @drimranomar]

Diagnostic Accuracy of Cystoscopy for Detecting Bladder Cancer in Adults Presenting with Haematuria .@Uroweb @MariaJRibal @ahmostafid @WoutDevlies @JoepJdeJong @maxbruins @EmmaJSmith9 @Cathyyuhongyuan @Phil_Violette @McMasterU Bas, Nancy, Tahilita, Fabian https://t.co/KgnaJm9keR

[Wout Devlies @WoutDevlies]

Proud on new paper from the Attard lab! Different novel insights in the PCa progression pathway.

[AttardLab @AttardLab]

Find out @AttardLab’s latest publication (https://t.co/c6HZ7WgBgU) showing that lethal prostate cancer progresses to lethal disease via a limited number (two or three) of dominant clones, each harbouring patient-specific androgen receptor gene architectures.

[Gaëtan Devos @devos_gaetan]

Very proud to present the ARNEO study published in @EUplatinum!!

In high-risk PCa patients, neoadjuvant degarelix plus apalutamide prior to RP results in significantly improved pathological response compared to degarelix alone!
@joniau

A thread🧵👇:
https://t.co/6JG17AiV5u

[AttardLab @AttardLab]

Great opportunity for a trainee oncologist to join our team and become an expert on prostate cancer: https://t.co/vygxQpGU0I

[Alumkal Lab @AlumkalJoshi]

Excited to share our new work on clinical enzalutamide resistance and lineage plasticity (LP) in prostate cancer through the @SU2C_PCF_WCDT out now in @NatureComms!
https://t.co/ZESxq082OP
@UMRogelCancer, @UMichCancBio, @umichrna, @PCF_Science, @DRSNmoonshot

[UroToday.com @urotoday]

#ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk #ProstateCancer. Presentation by @joniau @UZLeuven. #EAU22 written coverage by @zklaassen_md @GACancerCenter > https://t.co/IXQOND96Rm @Uroweb

[Wout Devlies @WoutDevlies]

@NPortaStat @ICR_CTSU Much deserved! Thank you very much sharing the statistical insights we all needed!

[Wout Devlies @WoutDevlies]

Excited for this intensive week designing a follow-up trial for the ARNEO study among many brilliant researchers! @joniau @EORTC

[EORTC @EORTC]

And so, after a 2 years delay, we’re getting ready for the next #mccrworkshop.

6 intensive days working on #clinicaltrial protocols.

[Wout Devlies @WoutDevlies]

Congrats Diogo to a very interesting set of neoadjuvant treated PCa, nicely complementary to our ARNEO study. Excited to see your future work. @MolendoKUL @joniau @devos_gaetan

[Diogo Assed Bastos @DiogoAssed]

Happy to share the results of our randomized phase II of intense ADT prior to prostatectomy for high-risk prostate cancer, including PSMA/PET correlation with path outcomes! @DrRanaMcKay @Silke_Gillessen @SoaresAndrey @RafaelFCoelho2 @montypal @g_develasco @DRathkopf

[Wout Devlies @WoutDevlies]

A very interesting read from our collaborators on liquid biopsy testing in prostate cancer: PCF select is a panel to watch! #prostatecancer @joniau @MolendoKUL

[PCF_SELECT @PCF_select]

.@PCF_SELECT #cfDNA assay detects #allelicimbalance (e.g. BRCA2, ATM, PTEN) in #prostatecancer plasma with high sensitivity. Consortium of @FrancescaBZNY @AttardLab @mishabeltran @ResearchWyatt @MarkARubin1 labs and teams! @PCF_Science @AIRC_it @CR_UK https://t.co/1Rw646GLWu

[Wout Devlies @WoutDevlies]

Want to learn more: https://t.co/gKBkkdNhng

[Wout Devlies @WoutDevlies]

Congrats to my colleague @DeBruynHelene for her passionate invited talk at @BIDMChealth @Harvard about developing murine models to truly investigate bladder function. Both invasive and non invasive models were welcomed with enthusiasm! @EveraertsW @licr_leuven